Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Novo Nordisk’s Wegovy should successfully overcome supply chain challenges by the end of 2022, says GlobalData

Novo Nordisk’s success in diabetes and obesity drug sales could be impacted by supply chain issues, for the production of its obesity drug Wegovy (semaglutide), unless it can resolve issues with its contract manufacturer says GlobalData. The leading data and analytics company expects Novo Nordisk to successfully overcome the supply challenges surrounding Wegovy in the second half of 2022 […]
Read more

Moderna’s vaccine could help prevent multiple sclerosis, says GlobalData

Following the recent discovery that infection with Epstein-Barr virus increases risk of developing multiple sclerosis (MS) by 32-fold, GlobalData highlights that there are currently 15 Epstein-Barr vaccines in development. Of these, the leading data and analytics company notes that Moderna’s mRNA-1189 is one of the most promising because it is being developed by a successful […]
Read more

AbbVie MDD drug Vraylar will have to compete with low-cost aripiprazole and quetiapine generics, says GlobalData

AbbVie has recently submitted a supplementary new drug application (sNDA) to the FDA for Vraylar (cariprazine) as the adjunctive treatment of major depressive disorder (MDD). However, pricey Vraylar will have to compete with low-cost aripiprazole and quetiapine generics, with competition becoming even fiercer when generic brexpiprazole enters the market in 2026, according to GlobalData, a […]
Read more

Combination trials featuring immune checkpoint inhibitors may not result in synergistic effects, says GlobalData

Increasingly, over the past decade pharmaceutical companies have sought to enhance the efficacy of Immune checkpoint inhibitors (ICIs) by using these in combination with other ICIs, chemotherapies, small molecules or cell therapies says GlobalData, the leading data and analytics company. ICIs are very widely used in oncology and include blockbuster drugs Merck & Co.’s Keytruda […]
Read more

Novel CAR-T cell approaches of Chinese pharma promote clinical innovation and can address remaining unmet needs, says GlobalData

Chinese pharma companies are continuously focusing on the research and development of new innovative oncology therapies. Recently, Innovent Biologics and Gracell Biotechnologies have initiated Phase I trials for their innovative chimeric-antigen receptor T (CAR-T) therapies. It could further address remaining unmet needs, says GlobalData, a leading data and analytics company. Gracell Biotechnologies’ GC012F is developed […]
Read more

AML treatment landscape in China evolving with availability of multiple precision therapy options, says GlobalData

China has recently approved CStone Pharmaceuticals’ Tibsovo (ivosidenib tablets) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, providing a new precision therapy for this patient population. With multiple precision therapies now available, the cancer treatment arsenal is expanding for adult acute myeloid leukemia […]
Read more

Early results highlight ZT-01’s ability to restore glucagon regulation in type 1 diabetics, says GlobalData

Zucara Therapeutics recently announced the publication of ZT-01 preclinical data for the treatment of insulin-induced hypoglycemia in patients with type 1 diabetes (T1D). Zucara is currently conducting a Phase 1b proof-of-concept clinical trial in people with T1D, with results anticipated in Q2 2022. With few therapeutics in development that focus on hypoglycemic prevention specifically, GlobalData […]
Read more

Ardelyx’s tenapanor has potential to capture a slice of the CKD-HP market, says GlobalData

Ardelyx’s tenapanor has the potential to capture a slice of the chronic kidney disease (CKD)-hyperphosphatemia (HP) market if the company can successfully appeal the Food and Drug Administration’s Appeal Denied Letter (ADL), says GlobalData. The leading data and analytics company notes that tenapanor’s potential is based on its ability to target dialysis-dependent patients who are […]
Read more

Novartis’ Leqvio has potential to lead the cholesterol-lowering space due to its administration convenience, says GlobalData

Sales for Novartis’ Leqvio (inclisiran) for the treatment of high cholesterol may surpass those of Sanofi/Regeneron’s Repatha (evolocumab) and Amgen’s Praluent (alirocumab) by 2027 due to its administration convenience, according to GlobalData. The leading data and analytics company notes that Leqvio is in a better position compared to its competitors as it is administered by […]
Read more
, ,

GlobalData partners with Snowflake to empower seamless access and delivery of its data

GlobalData’s Marketplace is now accessible via Snowflake’s cloud data platform, empowering seamless access and direct integration of GlobalData’s intelligence into customer applications and data operations.  London – February 21, 2022 – GlobalData Plc (LSE: DATA), a leading intelligence platform for the world’s largest industries, has announced a partnership with Snowflake, a premier data warehouse built […]
Read more

Promising pipeline drugs to transform the Fragile X Syndrome treatment market by 2030, says GlobalData

By 2030, GlobalData highlights that promising pipeline drugs Zygel, zatolmilast, trofinetide, and acamprosate calcium SR are set to offer new treatment options for people with Fragile X Syndrome (FXS)—a rare genetic disorder that is the leading cause of inherited intellectual disability. The leading data and analytics company notes that these products will help propel the […]
Read more

Haplo-cord treatment may provide permanent cure for over 37.7 million HIV sufferers, says GlobalData

Following the recent news that the woman referred to as ‘the New York patient’, who received haplo-cord treatment four years ago, is now off HIV medication and remains asymptomatic and healthy: Sultan Ahmed, Infectious Disease Analyst at GlobalData, a leading data and analytics company, offers his view: “The haplo-cord transplant, conventionally used for cancer treatment, […]
Read more

Global chronic myeloid leukemia market set to decline due to most medication losing patent protection by 2030, says GlobalData

The chronic myeloid leukemia (CML) therapy market is dominated by tyrosine kinase inhibitors (TKIs) targeting aberrant BCR-ABL1. However, with all but one of the currently marketed BCR-ABL1 TKIs due to lose patent protection by 2030, the global market is set to decline from $4.25 billion in 2020 to $3.35 billion in 2030, says GlobalData. According […]
Read more
1 … 49 50 51 52 53 … 108